Business Context and Reporting Period
This Form 8-K is a current report filed by Biocardia, Inc. on December 16, 2025. The filing addresses a significant regulatory milestone regarding the company's lead product candidate, CardiAMP Cell Therapy, intended for the treatment of Heart Failure with Reduced Ejection Fraction (HFrEF).
Key Financial Metrics
The filing text does not provide specific financial data, including revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on a regulatory development under Item 7.01 (Regulation FD Disclosure).
Material Changes
The primary material event reported is the completion of a third preliminary clinical consultation with Japan's Pharmaceutical and Medical Device Agency (PMDA). Key outcomes include:
- The PMDA has agreed to allow Biocardia to advance to a formal clinical consultation.
- Successful agreement during the formal consultation regarding safety and efficacy evidence could enable the company to file for regulatory approval in Japan.
Guidance, Outlook, and Risks
Outlook: The company's path to market in Japan is contingent upon the outcome of the upcoming formal clinical consultation. If the PMDA agrees that available data provides sufficient evidence of safety and efficacy, a regulatory approval filing will follow.
Risks and Contingencies: The filing implies that regulatory approval is not guaranteed and depends on the PMDA's assessment during the formal consultation. No specific financial risks or contingencies are detailed in this document.
Investor Verification Checklist
- Verify the specific timeline and agenda for the upcoming formal clinical consultation with the PMDA.
- Review the attached press release (Exhibit 99.1) for detailed data points discussed during the preliminary consultation.
- Monitor future filings for the results of the formal consultation and any subsequent regulatory filing dates.
- Check the company's most recent 10-Q or 10-K for current cash runway, as this 8-K does not disclose financial status.